These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 31371809)
1. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Bruix J; da Fonseca LG; Reig M Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):617-630. PubMed ID: 31371809 [TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Hollebecque A; Malka D; Ferté C; Ducreux M; Boige V Eur J Cancer; 2015 Feb; 51(3):327-39. PubMed ID: 25559615 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
6. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441 [TBL] [Abstract][Full Text] [Related]
8. Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Brown ZJ; Hewitt DB; Pawlik TM Expert Opin Investig Drugs; 2022 Jul; 31(7):693-706. PubMed ID: 35580650 [TBL] [Abstract][Full Text] [Related]
9. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146 [TBL] [Abstract][Full Text] [Related]
10. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Kim R; Byrne MT; Tan A; Aucejo F Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473 [TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Oikonomopoulos G; Aravind P; Sarker D Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762 [TBL] [Abstract][Full Text] [Related]
13. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK; BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194 [TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma]. Kondo S; Ueno H; Morizane C; Okusaka T Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702 [TBL] [Abstract][Full Text] [Related]
16. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. Villanueva A J Hepatol; 2013 Aug; 59(2):392-5. PubMed ID: 23548196 [TBL] [Abstract][Full Text] [Related]
17. An update on clinical trials in the treatment of advanced hepatocellular carcinoma. Lee JK; Abou-Alfa GK J Clin Gastroenterol; 2013 Jul; 47 Suppl():S16-9. PubMed ID: 23751800 [TBL] [Abstract][Full Text] [Related]